Post on 17-Jan-2016
transcript
www.ias2011.org
Evidence for the link between markers of inflammation, coagulation and immune
activation and end organ disease
Session: Immune Activation/Inflammation and HIV DiseaseIAS Conference, Rome, July 2011
Jens Lundgren, MD
Chair – INSIGHT’s scientific steering committeeProfessor – Univ. of Copenhagen
Chief physician – Copenhagen University HospitalDirector – Copenhagen HIV Programme
www.ias2011.org
Linking markers to organ disease:prognostic and surrogate biomarkers
• Prognostic marker– Predicts the risk of disease
• Causal: marker of process involved in pathogenesis• Epiphenomenon: not linked causally (e.g. subclinical stages
of disease itself raises levels)• Surrogate marker
– Change in level reflects the extent of benefit of an clinically beneficial intervention• Occurs sooner after intervention is initiated than the disease
– Surrogates are usually prognostic markers, but the opposite is seldom true
www.ias2011.org
Validation of surrogate biomarkers
Associated with Clinical
Events
[Case-control or Cohort Studies]
Modify with
Treatment
[Biomarker Studies (Phase II/Pilot/
Vanguard Studies)]
Markers that can be reliably measuredStored specimensProspectively identified and adjudicated eventsExcellent follow-upStudy is large enough to do nested case-controlled studies
[Clinical Trials with Clinical Outcomes]
Rx Effect on Biomarkers Predicts
Rx Effect on Clinical Events
www.ias2011.org
Median CD4+ During Follow-up
0 0.33
0.670000000000001
1 1.33
1.67
2 2.33
2.67
3 3.33
3.67
4 4.33
4.67
5 5.33
5.67
6 6.33
6.67
70
100
200
300
400
500
600
700
800
IL-2Control
Year
CD
4+
cell
co
un
t (
/µL
)
Avg Difference:160 cells, p<.001
Time spent IL-2 Control
< 300 cells 6% 9%
> 600 cells 57% 36%
IL-2: 2071 1846 1829 1797 1757 1721 1410 878
Control: 2040 1928 1861 1803 1739 1648 1350 824
No. pts
ESPRIT/INSIGHT study group, NEJM 2009
www.ias2011.org
Primary EndpointOpportunistic Disease or Death
IL-2 ControlNo. Rate* No. Rate* HR (95% CI) p-value
158 1.13 165 1.21 0.93 (0.75, 1.16) 0.52
Predicted HR based on CD4+ difference = 0.74
* rate per 100 person years
ESPRIT/INSIGHT study group, NEJM 2009
www.ias2011.org
Soluble Biomarkers of Inflammation & Coagulation in HIV
Biological process: Name of marker: Marker of:
Activation of:
immune cells, endothelium, platelets, and coagulation
Interleukin-6 hs-CRPsCD14D-dimerP-selectinsCD40 ligand
LymphocyteAcute phase reactantMacrophage/monocytefibrinolysisplatelets + endotheliumplatelets + endothelium + lymphocytes
Organ dysfunction
hyalyronic acid, FIB-4 NT-proBNPADMAeGFR, protinuria
LiverHeartEndotheliumkidney
www.ias2011.org
ESPRIT and SMART Control Group: Deaths by D-dimer Quartile at Study Entry
ESPRIT SMARTD-dimer levels:>0.38 g/mL0.26-0.380.19-0.25<0.19
D-dimer levels:>0.37 g/mL0.22-0.370.13-0.21<0.13
www.ias2011.org
ESPRIT Control Group: Hazard Ratios (D-dimer Q4/Q1) for Death by 4-Year Intervals
1
10
100H
R (
4th/
1st
Qua
rtile
)
p-value = 0.18 for change in HR over follow-up
1st 4 years follow-up > 4 years follow-up
# deaths, quartile 4: 15 24
# deaths, quartile 1: 4 4
HR (95% CI): 3.48 (1.2-10.5) 5.59 (1.9-16.1)
www.ias2011.org
OR for Mortality Associated with Baseline Biomarker Levels for Early (0-2 years) and Late
(2 > years) Deaths in SMART
Odd
s Ra
tio (4
th/1
st Q
uarti
le)
Paton et al, IAS 2009 (#MOPEA034)Paton et al, IAS 2009 (#MOPEA034)
hsCRP IL-6 D-dimer
Median Level (IQR) ≤ 2 yr > 2 yr ≤ 2 yr > 2 yr ≤ 2 yr > 2 yr
Deaths 3.13 (1.57-7.35)
3.69 (1.5-7.51)
3.58 (2.13-6.86)
3.72 (2.51-5.50)
0.45 (0.24-1.06)
0.31 (0.21-0.55)
Controls 2.08(0.83-4.83)
1.93 (0.84-5.11)
2.14(1.38-3.16)
2.33 (1.53-3.48)
0.24 (0.15-0.45)
0.24(0.15-0.38
# Deaths/Controls 95/188 71/137 92/184 67/133 94/188 69/128
www.ias2011.org
Association with risk of death is reduced the longer the time from measurement of
biomarker in persons with peripheral arterial disease
Vidula et al, Ann Intern Med 2008
www.ias2011.org
Trajectories in d-dimer Levels in ESPRIT Control Group at study entry, 12 and 36 Months
N=244
UpperLimit ofnormal
% above ULN(0.25 µg/mL)
39% 39% 42%
No significant change over time
www.ias2011.org
ESPRIT and SMART Control Group: Hazard Ratios for Quartiles (4th vs. 1st)
of D-dimer Levels at Study EntryESPRIT SMART
Event HR P-value HR P-value
Death 4.5 <.0001 6.0 .0007
AIDS 1.7 .23 5.3 .007
CVD 2.0 .11 2.7 .009
Non-AIDS malignancy 1.8 .14 1.3 .52
Serious Non-AIDS (SNA) 2.4 .003 2.0 .009
SNA or death from non-AIDS 2.3 .0007 2.6 .0002
www.ias2011.org
Change in D-Dimer* from Study Entry to 1 Month
0
0,1
0,2
0,3
≤ 400 401-10,000 10,000-50,000 >50,000
Month 1 HIV RNA Level (copies/mL)
∆ D
-Dim
er (
µg
/mL
)
P=.0005 for trend
* DC patients on ART at baseline with HIV RNA ≤ 400 copies/mL
Kuller et al, PLoSMed 2008
www.ias2011.org
D-dimer Levels After Starting ARTin SMART
-0.51
-0.30
0.00
-1
0
1
∆ D
-dim
er (
log
e µ
g/m
L)
P=0.02 for trend
≤ 400(n=77)
401-10,000(n=25)
Month 6 HIV-RNA Level (copies/mL)
>10,000 (n=22)
All participants were off ART at baseline (n=254) Randomized comparison of immediate ART (VS; n=128) or
deferral (D
No difference in IL-6 and hsCRP
All participants were off ART at baseline (n=254) Randomized comparison of immediate ART (VS; n=128) or
deferral (D
No difference in IL-6 and hsCRPBaker et al JAIDS 2011
www.ias2011.org
SMART: Comparison of Associations with Different Outcomes: Univariate ORs
(4th versus 1st quartile) – Case-Control Analyses
All cause mortality CVD AIDS
D-dimer 12.3 1.9 2.0
IL-6 11.7 3.7 1.7
Small HDL particles 0.13 0.50
sCD14 6.0 1.7 1.4
Total HDL particles 0.18 0.44
www.ias2011.org
Cellular markers of end organ disease in HIV
• Activation of CD4 and/or CD8 cells and markers of organ disease (cross-sectional studies)– Intima-media thickness (Hsu et al, AIDS 2006, Kaplan et al, JID 2011) and
arterial stiffness (Kaplan et al, Atherosclerosis 2011)• Linked to AIDS/death events
– In cross sectional analysis: • OR= 1.94 for risk of AIDS/death by 17% more %CD8+/HLA-
DR+/CD38+ (Kalayjian et al, JID 2010) • OR=6.5 for AIDS for 4th vs 1st quartile (Smurzynski et al, JAIDS 2010)
– In cohort studies• HR=1.61, P=0.042 (Hunt et al, CROI 2011)
• Still unclear– prognostic marker for organ disease– changes reflect surrogacy for benefit from interventions
www.ias2011.org
Use of markers in routine clinical practise
• Identify persons at increased risk of disease– Intriguing that D-dimer levels predict risk after multiple years– Unclear which interventions specifically benefits such patients over-
and-above benefits from common interventions used in internal medicine
– Will cause concern• Surrogates of interventions
– Remains to be established
Markers of inflammation and coagulationremains a research tool and
are not yet ready for routine use in HIV medicine
www.ias2011.org
Summary
• Many markers are prognostic but very few are surrogates of benefit for clinically useful interventions– Establishment of surrogacy is critical when assessing for
potentially useful anti-inflammatory interventions• This research requires large clinical endpoint driven RCT’s
• Soluble markers of inflammatory and coagulation• long-term risk of – particularly fatal - end-organ disease• D-dimer: potential for surrogacy of benefits from ART
– additional research required (e.g. START) • Data emerging on cellular markers of inflammation• Markers of inflammation and coagulation:
– useful tools to advance co-morbidity research agenda, – role in routine clinical practise remains to be determined.
www.ias2011.org
Acknowledgements
• INSIGHT network incl. executive, scientific and operational committee members + international coordinating centres and affiliated sites– Jim Neaton, Jason Baker, Jacquie Neuhaus, Debby Wentworth,
Andrew Phillips, Calvin Cohen and Steven Deeks• Peter Hunt, UCSF• Division of AIDS, NIAID
www.ias2011.org
UARTO: High CD8+ T Cell Activation at Month 6 of ART Predicts Subsequent Mortality in
Ugandans with VL<400
Hunt et al, CROI 2011 (306)
In Cox Proportional Hazards models, each 10% increase in the frequency of activated (%CD38+ HLA-DR+) CD8+ T cells was associated with an increased hazard of death even after adjustment for
baseline CD4 count (HR: 1.62, P=0.048) or month 6 CD4 count (HR: 1.61, P=0.042).